Volume 3, Issue 1 (7-2005)                   IJRM 2005, 3(1): 14-18 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ashrafi M, Moini A, Mohammadzadeh A, Ezabadi Z, Zafarani F, Baghestani A R. A comparative study of GnRH antagonist and GnRH agonist in PCO patients undergoing IVF/ICSI cycles. IJRM 2005; 3 (1) :14-18
URL: http://ijrm.ir/article-1-26-en.html
A comparative study of GnRH antagonist and GnRH agonist in PCO patients undergoing IVF/ICSI cycles
Mahnaz Ashrafi * , Ashraf Moini , Afsaneh Mohammadzadeh , Zahra Ezabadi , Fatemeh Zafarani , Ahmad Reza Baghestani
Abstract:   (3807 Views)
Background: Polycystic ovarian syndrome (PCOS) patients are prone to premature LH surge and ovarian hyperstimulation syndrome (OHSS). Long GnRH analogue protocol and GnRH antagonist protocol are two methods utilized for induction ovulation in patients undergoing IVF/ICSI. Objective: The aim of this study was to compare the effects of GnRH agonists and antagonists in PCOS patients. Materials and Methods: A total of 60 PCOS patients under 35 years old were enrolled in this study. The patients have no history of thyroid disorder and hyperprolactinemia. All patients received OCP (LD) before starting the treatment. Then patients randomly divided into two groups. The agonist group underwent standard long GnRH analogue protocol. In antagonist group, HMG (150 IU/day) was started from third day of cycle. Then GnRH antagonist (0.25mg) was administered from 6th day after HMG initiation (LH?5 IU/ml) to the day of HCG injection. Follicular development monitored by vaginal ultra sonography and serum estradiol measurement. Results: There were no significant differences in age, duration of infertility, BMI, number of HMG ampules, number of follicles?18mm, serum estradiol level on 6th day of HMG initiation and HCG injection time, fertilization and pregnancy rate between two groups. However there were significant differences regarding duration of treatment, duration of HMG usage, LH level at the initiation of HMG, OHSS rate and number of Metaphase II oocytes between two groups (p<0.05). Conclusion: Usage of the GnRH antagonist may have more advantages such as the shorter duration of treatment and less gonadotrophin requirement. Furthermore, the incidence of OHSS can be reduced in GnRH antagonist comparing to agonist. For decreasing the risk of OHSS and abortion rate, we recommend long term use of OCP before starting the treatment
Keywords: PCOS, GnRH agonist, GnRH antagonist, OHSS, IVF, ICSI
Full-Text [PDF 95 kb]   (745 Downloads) |   |   Full-Text (HTML)  (377 Views)  
Type of Study: Original Article |
References
1. Ron-EL R, Raziel A, Schachter M, Strassburger D, Kasterstein E, Friedler S. Induction of ovulation after GnRH antagonists. Human Rep Update 2000; 6(4): 318-321. [DOI:10.1093/humupd/6.4.318] [PMID]
2. Felberbaum R, and Diedrich K. The use of GnRH antagonist in IVF (Chap 18). In: Shoham Z, Howles CM, Jacobs HS. Female Infertility Therapy, London, Martin Dunitz 1999; 203-211.
3. Loumaye E. The control of endogenous secretion of LH by gonadotrophin-releasing hormone agonists during ovarian hyperstimulation for in vitro fertilization and embryo transfer. Hum Reprod 1990; 5: 357-376. [DOI:10.1093/oxfordjournals.humrep.a137105] [PMID]
4. Tirlatzis B, and Bili H. Antogonistic analogues of GnRH: preferable stimulating protocol In: Gardner DK, Weissman A, Howles CM, Shoham Z. Textbook of Assisted Reproductive Technique: Laboratory and clinical perspectives, First Ed. London, Martin Dunitz 2001; 493-500.
5. Fluker M, Grifo J, Leader A, Levy M, Meldrum D, Muasher SJ, et al. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril 2001; 75(1): 38- 45. [DOI:10.1016/S0015-0282(00)01638-1]
6. Barros Del Gadillo JC, Siebzehnrubl E, Dittrich R, Wildt L, Lang N. Comparison of GnRH agonists and antagonist in unselected IVF/ICSI patients treated with different controlled ovarian hyperstimulation protocols: a matched study. Europ J of Obs & Gynecol & Reprod Biol 2002; 102(2): 179-183. [DOI:10.1016/S0301-2115(01)00580-2]
7. The European and Middle East Orgalutran study group. Comparable Clinical outcome using The GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod 2001; 16(4): 644-651. [DOI:10.1093/humrep/16.4.644] [PMID]
8. Hwang JL, Seow KM, Lin YH, Huang LW, Hsieh BC, Tsai YL, et al. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane -35 pretreatment for patients with polycystic ovary syndrome: a prospective randomized study. Hum Reprod 2004; 19(9): 1993-2000. [DOI:10.1093/humrep/deh375] [PMID]
9. Adams J, Franks S, Polson DW, Mason HD, Abdulwahid N, Tucker M, et al . Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone. Lancet 1985; 2: 1375-1379. [DOI:10.1016/S0140-6736(85)92552-8]
10. Craft J, Gorgy A, Hill J, Menon D, Podsiadly B. Will GnRH antagonists provide new hope for patients considered (difficult responders) to GnRH agonist protocols? Hum Reprod 1999 ;14(12): 2959-2962. [DOI:10.1093/humrep/14.12.2959] [PMID]
11. Minaretzis D, Alper MM, Oskowitz SP, Lobel SM, Mortola JF, Pavlou SN. Gonadotropin- releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: cycle performance and in vitro Steroidogenesis of granulosa-lutein cells. Am J obstet Gynecol 1995; 172(5): 1518-1525. [DOI:10.1016/0002-9378(95)90490-5]
12. Albano C, Felberbaum RE, Smitz J, Riethmuller-Winzen H, Engel J, Diedrich K, et al. Ovarian stimulation with HMG: results of a prospective randomized phase Ш European study comparing the Luteinizing hormone releasing hormone (LHRH) -antagonist Cetrorelix and the LHRH-agonist Buserelin. European cetrorelix study group. Hum Reprod 2000; 15(3): 526-531. [DOI:10.1093/humrep/15.3.526] [PMID]
13. Hohmann FP, Macklon NS, Fauser BCJM. A randomized comparison of two ovarian stimulation protocols with Gonadotropin -releasing Hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol. J of Clin Endocrinol & Metab 2003; 88 (1): 166-173. [DOI:10.1210/jc.2002-020788] [PMID]
14. Garcia-Velasco JA, Isaza V, Vidal C, Landazabal A, Remohi J, Simon C, et al. Human ovarian steroid secretion in vivo: effects of GnRH agonist versus antagonist (cetrorelix). Hum Reprod 2001; 16(12): 2533-2539. [DOI:10.1093/humrep/16.12.2533] [PMID]
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Designed & Developed by : Yektaweb